OBJECTIVE: Obesity may be associated with increased markers of inflammation that could be triggered by metabolic, physical, infectious or environmental processes. As smoking significantly increases cytokine production, we aimed to study how smoking influences the relationship between fat mass and soluble tumor necrosis factor-a (TNF-a) receptors 1 and 2 (sTNFR1 and sTNFR2). DESIGN: Cross-sectional, clinical observational study. SUBJECTS: A total of 133 healthy men (age: 27-53 y, body mass index (BMI): 24-30.2 kg/m 2 ), 80 of whom were never-smokers and 53 smokers, matched for age, BMI and waist-to-hip ratio. MEASUREMENTS: Circulating soluble fractions of the TNF-a receptors sTNFR1 and sTNFR2 were measured to study their relationship with fat mass (bioelectric impedance). RESULTS: Smokers had significantly lower fat mass, lower fasting glucose, insulin and leptin concentrations than nonsmokers. Despite lower fat mass and insulin, smokers showed significantly increased circulating sTNFR2 levels (3.770.8 vs 3.470.7 ng/ ml, P ¼ 0.03). The slopes of the relationships between sTNFR1 and fat mass, and between sTNFR2 and fat mass, were significantly steeper in smokers than in nonsmokers. In a stepwise multiple linear regression analysis, both fat mass (Po0.00001) and smoking (P ¼ 0.025) independently contributed to 13% of sTNFR1 variance and to 4% of sTNFR2 variance (P ¼ 0.03). CONCLUSION: Both fat mass and smoking are related to increased activity of the TNF-a axis.
Obesity is increasingly recognized to be associated with several markers of inflammation. Positive associations among anthropometric indexes of adiposity, circulating proinflammatory cytokines and acute phase proteins have been described in the last few years. 1 This inflammation seems to be triggered by some metabolic, physical, infectious and environmental processes. Overwhelming evidence indicates that cigarette smokers, when compared with lifelong nonsmokers, are at a two-to three-fold increased risk of inflammatory cardiovascular disease. 2 Smoking exerts an inflammatory stimulus on macrophages which bring about the production of inflammatory cytokines, such as tumor necrosis factor-a (TNF-a), which might be an early event in the development of the disease states associated with smoking. 3 TNF-a is increasingly recognized to be involved in the pathogenesis of obesity. This cytokine is produced in excess by adipocytes of obese individuals. The activation of the TNF-a system seems to be associated with increased energy expenditure and weight loss in humans. 4, 5 Cigarette smoking is associated with a reduced body weight, 6 which might be due, at least in part, to increased activation of the TNF-a system. In fact, Tappia et al 7 had demonstrated that cigarette smoking influences TNF-a production in the blood from smokers exposed to endotoxin, which was elevated relative to that in nonsmokers by 38%. Thus, chronic overproduction of cytokines in response to smoking is a strong possibility because dose-dependent cigarette smoking-related inflammatory responses in healthy adults have consistently been described. 8 TNF-a stimulates leptin secretion in cultured adipocytes and in obese mice and, as a feedback loop, leptin administration to rats decreased TNF-a expression by 40%.
9-11 TNF-a administration increases serum leptin levels in humans 12 and plasma sTNFR1 concentration circulates in proportion to leptin. 13 The coordinated function of these two systems might be involved in controlling satiety and food intake. Serum leptin concentration in smokers has been described to be lower, 14,15 similar 16 or greater 17 than that found in nonsmokers. TNF-a binds to two TNF-a receptors, TNF-R1 and TNF-R2. Each receptor is expressed by most of the cells and can be regulated independently. After binding to its receptors, a proteolytic cleavage of the extracellular parts elicits the soluble forms named sTNFR1 (60 kDa) and sTNFR2 (80 kDa). 18, 19 In patients with sepsis, the sTNFRs were constantly found in the circulation representing the inflammatory state even when TNF activity was undetectable. 20 Measurements of the sTNFR concentrations in healthy individuals at different time lapses showed that the levels in the same subject were quite stable over time, 21 and have been validated as sensitive indicators of activation of the TNF-a system. 18 Plasma concentration of sTNFR2 strongly correlated with BMI in some 13, [22] [23] [24] but not all studies. 25 Similarly, circulating sTNFR1 levels were not associated with BMI, 13, 22, 23 although in other studies the relationship was significant. 24, 25 The independent contribution of smoking, as a confounding factor, on the relationship between fat mass and TNF system activation, as measured using circulating sTNFR1 and sTNFR2, has not been evaluated, despite the evidences that smoking alters cytokine production. As obesity per se is recognized as a chronic inflammatory state, with increased TNF system activation, we aimed to study how smoking influences the relationship between fat mass and sTNFRs.
Subjects and methods

Subjects
In all, 133 men were evaluated between July 1 and September 15, 1997, as part of the ongoing epidemiological study in Catalonia (Spain). None of the subjects were taking any medication or had any evidence of metabolic disease other than obesity. All subjects were of Caucasian origin and reported that their body weight had been stable for at least 3 months before the study; all were normotensive and normolipemic. The patients were consecutive and unselected except for fulfilling the following inclusion criteria: (1) Body mass index (BMI, weight in kg divided by the square of height in m) o40 kg/m 2 , (2) absence of any systemic disease, (3) absence of any infections in the previous month. A smoker was defined as any person consuming at least one cigarette a day in the previous 6 months. Former smokers were excluded from subsequent analysis. Never-smokers were defined as 100 or fewer cigarettes lifelong. Liver disease and thyroid dysfunction were specifically excluded by biochemical workup. The protocol was approved by the Hospital Ethics Committee, and informed consent was obtained from each subject. Subjects were instructed to withhold alcohol, smoking and food during at least 10 h prior to blood extraction. No specific recommendations were given regarding diet.
Anthropometric measurements
All subjects were evaluated through the BMI and the waistto-hip ratio (WHR). The subject's waist was measured with a soft tape midway between the lowest rib and the iliac crest. The hip circumference was measured at the widest part of the gluteal region.
Fat mass (FM) and per cent fat mass (PFM) were calculated using bioelectric impedance (Holtain BC Analyzer, UK).
Analytical methods
The serum glucose concentration was measured in duplicate by the glucose oxidase method. The serum insulin level was measured in duplicate by monoclonal immunoradiometric assay (IRMA, Medgenix Diagnostics, Fleunes, Belgium). The lowest limit of detection was 4.0 mU/l. The intra-assay coefficient of variation was 5.2% at a concentration of 10 mU/l. The interassay coefficient of variation was 4.5% at 14 mU/l.
The MEDGENIX sTNF-R1 and sTNF-R2 EASIAt (BioSource Europe SA, Zoning Industriel B-6220, Fleunes, Belgium) are solid-phase enzyme-amplified sensitivity immunoassays performed on a microtiter plate. The minimum detectable concentration was estimated to be 0.1 ng/ml, and was defined as the sTNFR1 or sTNFR2 concentration corresponding to the average OD of 20 replicates of the zero standard þ 2 standard deviations. The intra-and interassay coefficients of variation were o7 and o9% in the range of 1-7 ng/ml. sTNFR1 EASIA does not crossreact with sTNF-R2. TNF-a does not interfere with the assay.
Immunoreactive serum leptin concentrations were measured in samples obtained after an overnight fast, between 0800 and 0830 h (Linco Research Inc., St Charles, MO, USA). The lower limit of detection is 0.5 ng/ml. The coefficients of variation intra-and interassay were o7% and o8%, respectively.
Statistical analysis
Descriptive results of continuous variables are expressed as mean7s.d. Before statistical analysis, the normal distribution and homogeneity of the variances were tested. Parameters that did not fulfill these tests (sTNFR1, sTNFR2, leptin) were log-transformed. We used w 2 test for comparisons of proportions. Comparison of variables between groups of subjects was performed using Student's t-test.
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Relationships between variables were also sought by partial correlation analysis and stepwise multivariate linear regression analysis with forward selection. Smoking status was introduced as a categorical variable (0, no smoker; 1, smoker). The relationship between BMI and TNFR1 was also assessed by means of a multilevel model. In particular, two levels were considered regarding the smoking status (current smoker and current nonsmoker). The idea was that not only the baseline BMI (ie that not determined by the covariates), but also the relationship between BMI and its covariates, varied between levels. The possible relationship was controlled for age. Levels of statistical significance were set at Po0.05.
Results
Anthropometric and biochemical characteristics of the study subjects are shown in Table 1 . The histogram of cigarette consumption in the population studied is shown in Figure 1 . Smokers were similar in age, BMI and WHR, and had significantly lower fat mass, lower fasting glucose, insulin and leptin concentrations than nonsmokers (Table 1 ). Of note was that smokers also showed significantly higher circulating sTNFR2 levels than nonsmokers (3.770.8 vs 3.470.7 ng/ml, P ¼ 0.03).
The relationships between BMI and sTNFR1 (r ¼ 0.10, P ¼ 0.38) or between fat mass and sTNFR1 (r ¼ 0.12, P ¼ 0.28) were not statistically significant among nonsmokers. The relationships for smokers, by contrast, were always statistically significant and the coefficient was higher than for nonsmokers (r ¼ 0.51, P ¼ 0.001 for BMI; r ¼ 0.56, Po0.0001 for fat mass; Figure 2 ). Similar findings were observed for sTNFR2: r ¼ 0.43, P ¼ 0.003 for BMI; r ¼ 0.30, P ¼ 0.04, for fat mass, in smokers; r ¼ 0.03, P ¼ 0.75 for BMI; r ¼ 0.003, P ¼ 0.97, for fat mass, in nonsmokers. We explored the possible dose-response between cigarette consumption and sTNFRs. A simple correlation analysis showed no significant associations between the number of cigarettes a day and sTNFR1 or sTNFR2. However, after controlling for fat mass, the association between sTNFR2 and the number of cigarettes a day became significant (r ¼ 0.33, P ¼ 0.002). Moreover, in those subjects who smoked less than 20 cigarettes a day, sTNFR2, but not sTNFR1, was significantly associated with cigarette consumption (Figure 3) .
In a stepwise multiple linear regression analysis, both fat mass (8%) (Po0.00001) and smoking (5%) (P ¼ 0.025) independently of fasting insulin contributed to 13% of sTNFR1 variance. Furthermore, 4% of sTNFR2 variance was explained by smoking in men (P ¼ 0.03), independently of fat mass and insulin concentration. Smoking and TNF system J-M Fernandez-Real et al
Discussion
The main finding of this study is that the association between fatness and the activity of the TNF axis was dependent on smoking in apparently healthy men. Soluble TNF-a receptors were strongly associated with adiposity in smokers, who also had significantly higher sTNFR2 concentration than nonsmokers. Although the difference observed seemed quite small, it may be biologically significant because of the lower fat mass of smokers. Taking into account that smokers were thinner and had lower glucose and insulin levels, and that both BMI and insulin resistance have been demonstrated to increase sTNFR2 levels, 23 those sTNFR2 levels found in smokers were disproportionately higher than those observed in nonsmokers. Soluble TNF-a receptors have also been demonstrated to be affected by BMI and smoking in psychiatric patients in a recent report. 26 The findings of the present study may help to explain the discrepant relationships among sTNFR1, sTNFR2 and adiposity measures. 13, [22] [23] [24] [25] The latter could be attributed to the inclusion of different proportions of smokers in the different studies. 13, [22] [23] [24] [25] Activation of the TNF-a system is associated with increased energy expenditure and weight loss in humans, 4, 5 but this seems to be in contrast with the increased TNF-a mRNA expression of adipose tissue, and increased circulating TNF-a, sTNFR1 and sTNFR2 of obese subjects, 13, 23, 24 in whom no weight loss is observed. The TNF-a content of the gingival crevicular fluid from smokers was significantly increased compared with nonsmokers. 27 The stimulus for TNF-a secretion might be derived from a component recently described in cigarette smoke itself: endotoxin (LPS). 28 LPS is one of the most potent biologic response modifiers currently recognized, and possesses a multitude of effects, most notably the initiation of a proinflammatory cascade, stimulating the production and release of cytokines, chemokines and eicosanoids. LPS is extraordinarily ubiquitous in nature, being present in normal indoor environments as a constituent of house dust. 29 Intravenous administration of LPS to healthy volunteers caused a marked increase in sTNFR1 and sTNFR2. 30 The origin of the associations described in this study might be due to direct activation of TNF-a secretion caused by smoking. Repeated exposure to LPS can induce tolerance in target cells. 31 The observed steeper slope of relationship between fat mass and circulating sTNFRs in smokers suggests chronic activation of the TNF-a system in smokers. Repeated exposure to environmental LPS (smoking) might also be hypothesized to contribute to TNF-a tolerance through increased sTNFRs in some obese subjects. However, other components of cigarette smoke (oxidant gases: nitric oxide, ozone and nicotine) and/or physical factors (thermal exposure, inhalation of particles) could contribute to the inflammatory effects of smoking in the specific activation of the TNF pathway. In a previous study, no significant differences were shown in circulating sTNFR1 or sTNFR2 between smokers and nonsmokers. 28 This could be due to the relatively small sample size in that study and also differences in patient selection, sex and adiposity between groups (smokers and nonsmokers were matched only for age).
In conclusion, the data indicate that both fat mass and smoking are related to increased activity of the TNF-a axis. Smoking and TNF system J-M Fernandez-Real et al
